Atezolizumab (Tecentriq) Tops Chemo for Platinum-ineligible NSCLC

The checkpoint inhibitor was associated with better survival and adverse events vs single-agent chemo for advanced NSCLC. The study was published as a preprint and has not yet been peer reviewed.
First Look

source https://www.medscape.com/viewarticle/986602?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

New AAFP practice guideline sets blood pressure targets for adults with hypertension

Heart Failure Care Outside of ICU Can Lower Cost